Cancer

Study: Cancer Jab Eliminates Tumors in Patients

Is amivantamab a genuine breakthrough for head and neck cancer patients or a promising drug that demands cautious optimism?

Published MAY 31

Study: Cancer Jab Eliminates Tumors in Patients

Story

Above: A tumor is detected using an MRI at the radiology department of the University Medicine in Rostock, Germany, on Nov. 17, 2017. Image credit: Bernd Wüstneck/picture alliance/Getty Images

The Spin

Narrative A

Amivantamab is a genuine breakthrough for head and neck cancer patients who've exhausted every other option — tumors shrank in more than a third of patients, and survival stretched to a median of 12.5 months versus the typical three to six. A quick five-minute injection every three weeks with minimal side effects makes this treatment far more livable than chemotherapy, and it has the potential to help thousands of patients annually.

The Telegraph

Narrative B

Amivantamab's trial results deserve cautious optimism, not celebration — only 15 of 102 patients saw tumors fully disappear, and the real test comes when this drug moves beyond tightly controlled trial conditions. The subcutaneous delivery and mild side-effect profile are genuinely promising practical advantages, but headline numbers like "tumors eliminated" create pressure to expand use beyond patients most likely to benefit.

Corax on X